Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines

Maria A. Pelidis, Michael A. Carducci, Jonathan W. Simons

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Sodium phenylbutyrate (NaPB) is used in urea cycle disorders. We screened 6 neuroblastoma cell lines for in vitro potency of NaPB as an antiproliferative agent, evaluated multiple dosing schedules, and assessed its activity in combination with clinically active agents for neuroblastoma. We determined that NaPB achieves a 30-80% growth inhibition at 5 mM. Repeated dosing and prolonged drug exposure enhanced the cytotoxic effect. NaPB had additive cytotoxic effects when administered with vincristine; however, NaPB did not affect the activity of etoposide, adriamycin, 4-hydroxy- cyclophosphamide or cisplatinum. These results suggest that NaPB is an active agent against neuroblastoma and could be combined with vincristine in novel chemotherapy regimens.

Original languageEnglish (US)
Pages (from-to)889-893
Number of pages5
JournalInternational journal of oncology
Issue number4
StatePublished - Apr 1998


  • Differentiation
  • Growth inhibition
  • Neuroblastoma
  • Sodium phenylbutyrate
  • Vincristine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines'. Together they form a unique fingerprint.

Cite this